Admera Health Named Best Biotechnology Business of the Year 2026 in the United States

July 17, 2026

•

5 min read

Share this post

Admera Health has been named Best Biotechnology Business of the Year 2026 | United States in the Global 100 – 2026 awards, recognising a company that has built its reputation on scientific rigor, hands-on collaboration, and an unwavering commitment to keeping sensitive biomedical work entirely on US soil. For research teams balancing timelines, budgets, and the need for trustworthy results, Admera’s approach stands out: it aims to operate as a true scientific partner, not a commodity sequencing vendor.

A full-service genomics and multi-omics partner built for research realities

Modern life-science research moves quickly, and projects rarely fit a one-size-fits-all workflow. Admera Health positions itself as a full-service genomics and multi-omics provider supporting a wide range of study designs—from early discovery through translational work—by pairing broad technology capabilities with consultative, scientist-to-scientist engagement.

According to the company, Admera supports a deep menu of omics capabilities, spanning technologies such as single-cell, spatial transcriptomics, RNA sequencing, and whole genome and whole exome sequencing, among others. Just as importantly, the company emphasizes that its teams work alongside clients from experimental design through to analysis and interpretation, with PhD-level scientific support embedded into projects rather than limited to a sales handoff.

US-based operations and data stewardship as a differentiator

In an era where data governance, privacy, and research integrity are under heightened scrutiny, Admera Health’s message is direct: it operates as a 100% US-based organization, with samples, laboratory work, and data handled domestically. For many institutions—particularly those managing human samples, sensitive IP, or compliance-heavy workflows—this operating model can reduce friction and risk.

Admera also stresses robust security and compliance standards to protect client data and ensure dependable project execution. In practical terms, that focus is designed to give researchers confidence that the chain of custody, lab processes, and downstream bioinformatics are managed within a controlled and consistent environment.

Scientific rigor supported by laboratory accreditations

Quality is a recurring theme in Admera’s positioning. The company highlights that it is CLIA and CAP-certified, aligning its laboratory practices with widely recognised standards in regulated testing environments. It also notes its re-accreditation by the College of American Pathologists, reinforcing ongoing quality oversight.

For research groups and industry teams alike, these credentials can matter because they signal controlled processes, documentation discipline, and a culture of continual assessment—especially valuable when results may influence downstream decision-making.

Platform breadth that supports evolving study designs

Admera Health describes a technology portfolio spanning more than 30 omics technologies, designed to support diverse sample types, experimental approaches, and levels of biological resolution. As multi-omics becomes increasingly central to high-impact research, access to a broad toolkit can help teams build studies that are both ambitious and practical.

Capabilities highlighted by Admera include:

Single-cell sequencing to resolve cellular heterogeneity and map complex tissues
Spatial transcriptomics to link gene expression with tissue architecture
Long-read sequencing with PacBio, with Admera noting fast turnaround and certified service-provider status
RNA-seq for expression profiling across research applications
Whole genome sequencing (WGS) and whole exome sequencing (WES) to support variant discovery and genomic characterization
Integrated bioinformatics analysis to translate raw data into usable scientific outputs

In addition, Admera points to its role in advancing access to emerging platforms over time, citing early involvement in single-cell services and leadership in bringing newer sequencing systems into service workflows.

Consultative culture: “scientist-to-scientist” support

Sequencing and omics projects often fail or underdeliver not because the instruments are inadequate, but because the experimental design, sample preparation strategy, or analysis plan was misaligned with the biological question. Admera Health’s model is built around avoiding those pitfalls through consultative project support, including a free scientist-led project consultation offered to clients.

This approach can be particularly valuable for complex projects such as single-cell studies, spatial workflows, or long-read applications—where decisions around sample quality, library prep selection, and analysis pipelines can materially affect conclusions. By embedding PhD scientists across the project lifecycle, Admera aims to help clients make high-confidence choices early, reducing costly rework and shortening time to insight.

Strengthening end-to-end capabilities through BioEcho

Admera Health also highlights its acquisition of BioEcho Life Sciences in 2024, a move intended to deepen end-to-end capabilities through nucleic acid purification technology. The company references the EchoLUTION product line and related extraction and purification expertise, including:

EchoLUTION Plant DNA
EchoLUTION Cell Culture RNA

For researchers, upstream sample and nucleic acid quality is often the hidden determinant of downstream success. Strengthening those early workflow stages can improve data quality, reduce variability, and support more reliable multi-omics outputs.

Partnerships, programs, and applied research momentum

Beyond service delivery, Admera cites involvement in broader initiatives that reflect how omics capabilities are increasingly used across societal and translational contexts. The company notes its approval for AWS Social Impact and Sustainability Program credits, positioning this as recognition of its role in enabling equity-driven research globally.

Admera also points to collaboration in Alzheimer’s research, including a partnership with Old Dominion University involving an AI platform aimed at advancing research in this area. As the field explores how multi-omics data and machine learning can work together to accelerate discovery, such collaborations illustrate the growing convergence between biotechnology and data science.

Why Admera Health stands out in a crowded market

Across biotechnology, “faster” and “cheaper” can be tempting promises—but many research leaders ultimately prioritize repeatability, transparency, and expert support. Admera’s distinction, as described by the company, is an intentional departure from assembly-line outsourcing: an all-US operating model, accredited lab standards, and a consultative team that treats each project with the care it would give its own.

For academic labs, core facilities, and industry R&D teams looking for a dependable genomics partner, the message is consistent: data quality, speed, and scientific collaboration don’t have to be trade-offs.

Global 100 – 2026 recognition

Being named Best Biotechnology Business of the Year 2026 | United States in the Global 100 – 2026 awards reflects Admera Health’s standing as a trusted genomics and multi-omics partner for researchers who cannot compromise on quality, security, or scientific depth. As omics continues to reshape how the world approaches discovery and precision research, Admera’s emphasis on rigor and collaboration positions it to remain a go-to choice for teams aiming to turn complex biological questions into actionable insight.